Effect of statins pretreatment on periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: A meta-analysis

Annals of Medicine

Volumn 42, Issue 3, 2010, Pages 171-177

  Zhang, Feng ^a   Dong, Lili ^a   Ge, Junbo ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Coronary artery disease; Hydroxymethylglutaryl CoA reductase inhibitor; Percutaneous coronary intervention; Statins

Indexed keywords

STATIN;

ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; DATA BASE; DEATH; EMBASE; FOLLOW UP; HEART INFARCTION; HUMAN; MEDLINE; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; Q WAVE; REVASCULARIZATION; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77950843983     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890903463976     Document Type: Article

References (37)

1. Herrmann J. Peri-procedural myocardial injury: 2005 update. Eur Heart J. 2005;26:2493-2519
2. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/ WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J. 2007;28:2525-2538 (Pubitemid 47616190)
3. Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol. 2003;42:1406-1411
4. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2004;110:674-678
5. Briguori C, Colombo A, Airoldi F, Violante A, Focaccio A, Balestrieri P, et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J. 2004;25:1822-1828
6. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 20 07;49:1272-1278
7. Yun KH, Jeong MH, Oh SK, Rhee SJ, Park EM, Lee EM, et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol. 2008 Aug 13 (Epub ahead of print).
8. Veselka J, Zemánek D, Hájek P, Maly M, Adlová R, Martinkovicová L, et al. Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study. Am J Cardiol. 2009;104:630-633
9. Briguori C. NAPLES (Novel Approaches for Preventing or Limiting Event Study) II Trial: Impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. Presented at 58th annual scientific session of American College of Cardiology 2009 in Orlando, USA on 30 March 2009. Available at: http://assets.cardiosource.com/ NAPLESII-Briguori.ppt. accessed on April 30th 2009.
10. Bozbas H, Yildirir A, Mermer S, Konas D, Atar I, Aydinalp A, et al. Does pravastatin therapy affect cardiac enzyme levels after percutaneous coronary intervention? Adv Ther. 2007; 24:493-504.
11. Hara H, Nakamura M, Yokouchi I, Kimura K, Nemoto N, Ito S, et al. Aggressive statin therapy in multicenter and effectiveness for the reduction of intra-myocardial damage caused by non-ST elevation acute coronary syndrome: AMERICA study. Ther Adv Cardiovasc Dis. 2009;3: 357-365
12. Egger M, Ebrahim S, Smith GD. Where now for metaanalysis? Int J Epidemiol. 2002;31:1-5.
13. Weintraub WS, Boccuzzi SJ, Klein JL, Kosinski AS, King SB 3rd, Ivanhoe R, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med. 1994;331:1331-1337
14. Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, et al. A randomized placebo-controlled trial of fl uvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fl uvastatin angiographic restenosis (FLARE) trial. Eur Heart J. 1999; 20:58-69.
15. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560
18. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50: 1088-1101
19. Akkerhuis KM, Alexander JH, Tardiff BE, Boersma E, Harrington RA, Lincoff AM, et al. Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? Circulation. 2002;105:554-556
20. Mulukutla SR, Marroquin OC, Smith C, Varghese R, Anderson WD, Lee JS, et al. Effect of statin therapy prior to elective percutaneous coronary intervention of frequency of periprocedural myocardial injury. Am J Cardiol. 2004;94:1363-1368
21. Herrmann J, Lerman A, Baumgart D, Volbracht L, Schulz R, von Birgelen C, et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation. 2002;106:2180-2183
22. Chang SM, Yazbek N, Lakkis NM. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcomes. Catheter Cardiovasc Interv. 2004;62:193-197
23. Chan AW, Bhatt DL, Chew DP, Reginelli J, Schneider JP, Topol EJ, et al. Relation of Inflammation and benefi t of statins after percuatneous coronary inteventions. Circulation. 2003;107:1750-1756
24. Auguadro C, Manfredi M, Scalise F, Mortara A, Specchia G. Protective role of chronic statin therapy in reducing myocardial damage during percutaneous coronary intervention. J Cardiovasc Med (Hagerstown). 2006;7:416-421
25. Gurm HS, Breitbart Y, Vivekanathan D, Yen MH, Fathi R, Ziada KM, et al. Preprocedural statin use is associated with a reduced hazard of postprocedural myonecrosis in patients undergoing rotational atherectomy-a propensity-adjusted analysis. Am Heart J. 2006;151 supple:1031-6.
26. Veselka J, Prochazkova S, Duchonova R, Homolova I, Tesar D, Bybee KA. Preprocedural statin therapy reduces the risk and extent of cardiac biomarker release following percutaneous coronary intervention. Heart Vessels. 2006;21:146-151
27. Ebrahimi R, Saleh J, Toggart E, Shah AP, Azmoon S, Babaei H, et al. Effect of preprocedural statin use on procedural myocardial infarction and major cardiac adverse events in percutaneous coronary intervention: a meta-analysis. J Invasive Cardiol. 2008;20:292-295
28. Ray KK, Cannon CP. Early time to benefi t with intensive statin treatment: could it be the pleiotropic effects? Am J Cardiol. 2005;96:54F-60F.
29. Wassmann S, Faul A, Hennen B, Sheller B, Bohm M, Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on coronary endothelial function. Circ Res. 2003;93:e98-103.
30. Hinoi T, Matsuo S, Tadehara F, Tsujiyama S, Yamakido M. Acute effect of atorvastatin on coronary circulation measured by transthoracic Doppler echocardiography in patients without coronary artery disease by angiography. Am J Cardiol. 2005;96:89-91.
31. Sanguigni V, Pignatelli P, Lenti L, Ferro D, Bellia A, Carnevale R, et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation. 2005;111: 412-419
32. Jones SP, Lefer DJ. Cardioprotective action of acute HMG-CoA reductase inhibition in the setting of myocardial infarction. Acta Physiol Scand. 2001;173:139-143
33. Notarbartolo A, Davì G, Averna M, Barbagallo CM, Ganci A, Giammarresi C, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15: 247-251
34. Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin Inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70.
35. Correia LC, Spósito AC, Lima JC, Magalhães LP, Passos LC, Rocha MS, et al. Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction. Am J Cardiol. 2003;92: 298-301.
36. Macin SM, Perna ER, Farías EF, Franciosi V, Cialzeta JR, Brizuela M, et al. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebocontrolled study. Am Heart J. 2005;149:451-457
37. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108: 1560-1566